GEN Exclusives

More »

GEN News Highlights

More »
Aug 7, 2012

Ab Fragment Imaging Firm Signs Singapore Deal

  • Antibody fragment imaging specialist ImaginAb signed a master service agreement with Singapore Radiopharmaceuticals, a Fortis HealthCare subsidiary that provides GMP radiopharmaceutical production services. ImaginAb is developing antibody fragment-based PET imaging agents for use in the clinical management of autoimmune diseases and cancer, and is establishing R&D and preclinical imaging capabilities in Singapore.

    "The deal with Singapore Radiopharmaceuticals represents a key component in this expansion program," comments Christian Behrenbruch, Ph.D., CEO. “Singapore Radiopharmaceuticals has an excellent track record in custom radiochemistry and cGMP product manufacturing, and we are pleased to transition our ad hoc collaboration to more robust alliance.”

    ImaginAb’s in-house pipeline includes early clinical-stage products for imaging and staging prostate, pancreatic, and breast cancers. The firm separately has over a dozen partnered programs in progress to develop companion diagnostic imaging agents for use alongside therapeutic antibody drugs in clinical trials. Partnered projects are exploiting the ability to reengineer a therapeutic monoclonal antibody or antibody-drug conjugate into an imaging agent that retains the same biospecificity of the parent product, but exhibits kinetics suitable for clinical imaging using low-cost isotopes. ImaginAb claims this ability to develop imaging antibodies that retain the same binding characteristics as the therapeutic antibody could represent a transformative technology for patient selection, monitoring treatment responses and looking for new therapeutic indications for antibodies.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Patients Access to Experimental Medicines?

More »